Stockscreener 앱 받기
0.279
5.74%
-0.017
시간 외 거래:
.28
0.001
+0.36%
전일 마감가:
$0.296
열려 있는:
$0.3
하루 거래량:
2.74M
Relative Volume:
1.00
시가총액:
$47.41M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-0.186
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
-18.33%
1개월 성능:
-18.82%
6개월 성능:
-80.49%
1년 성능:
-85.84%
1일 변동 폭
$0.279
$0.305
1주일 범위
$0.279
$0.3581
52주 변동 폭
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.279 | 47.41M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World
Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World
Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World
Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa
Mersana reports promising Phase 1 ADC trial results - Investing.com India
Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus
Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq
Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance
Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada
Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister
Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan
Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | M - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com Australia
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights - GuruFocus
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mersana Therapeutics Inc 주식 (MRSN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
0.39%
0.42%
자본화:
|
볼륨(24시간):